UPDATE: Ladenburg Thalmann Lowers AMAG Pharmaceuticals PT

According to a research report published earlier today, Ladenburg Thalmann has lowered AMAG Pharmaceuticals'

PT from $19.50 to $19. Ladenburg Thalmann said in the report, “We continue to believe AMAG's valuation continues to be partially sustained by investor expectations for a potential acquisition or other commercial strategic move(s). To this end, we believe the Street (and us) assigns a high probability of success to the ongoing label expansion initiative to include general iron deficiency anemia (

). We expect data from the first Feraheme Phase 3 trial in general IDA later this week.” Ladenburg Thalmann maintains its Buy rating on AMAG Pharmaceuticals, which closed yesterday at $16.09.